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Summary
Tissue branching morphogenesis requires the hierarchical
organization of sprouting cells into leading ‘‘tip’’ and trailing
‘‘stalk’’ cells [1, 2]. During new blood vessel branching
(angiogenesis), endothelial tip cells (TCs) lead sprouting
vessels, extend filopodia, and migrate in response to gradi-
ents of the secreted ligand, vascular endothelial growth
factor (Vegf) [3]. In contrast, adjacent stalk cells (SCs) trail
TCs, generate the trunk of new vessels, and critically main-
tain connectivity with parental vessels. Here, we establish
that h2.0-like homeobox-1 (Hlx1) determines SC potential,
which is critical for angiogenesis during zebrafish develop-
ment. By combining a novel pharmacological strategy for
the manipulation of angiogenic cell behavior in vivo with
transcriptomic analyses of sprouting cells, we identify the
uniquely sprouting-associated gene, hlx1. Expression of
hlx1 is almost entirely restricted to sprouting endothelial
cells and is excluded from adjacent nonangiogenic cells.
Furthermore, Hlx1 knockdown reveals its essential role in
angiogenesis. Importantly, mosaic analyses uncover a cell-
autonomous role for Hlx1 in the maintenance of SC identity
in sprouting vessels. Hence, Hlx1-mediated maintenance of
SC potential regulates angiogenesis, a finding that may
have novel implications for sprouting morphogenesis of
other tissues.Results and Discussion
To identify previously unknown determinants of endothelial
cell (EC) sprouting, we defined and exploited a pharmacolog-
ical strategy for the manipulation of angiogenic cell behavior
in vivo. Whereas high vascular endothelial growth factor
receptor (Vegfr) signaling is known to promote tip cell (TC)
specification, activation of the Notch receptor via its ligand
Delta-like 4 (Dll4) represses the TC phenotype to promote stalk
cell (SC) fate [4–6]. Conversely, suppression of Notch activity
upon antagonistic interaction with its ligand Jagged1 pro-
motes TC formation [7]. Hence, specification of TCs involves
tight spatiotemporal control of Vegfr/Notch signaling [8]. Con-
sequently, we hypothesized that the pharmacological manipu-
lation of Vegfr/Notch signaling selectively during zebrafish3Present address: Faculty of Life Sciences, University of Manchester,
Michael Smith Building, Oxford Road, Manchester M13 9PT, UK
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stainier@ucsf.edu (D.Y.R.S.)intersegmental vessel (ISV) angiogenesis would enable the
precise control of angiogenic EC behavior and sprouting-
associated gene expression in vivo. In control dimethyl sulf-
oxide (DMSO)-treated Tg(kdrl:GFP)s843 embryos [9], green
fluorescent protein (GFP)-expressing ECs sprout by angiogen-
esis at regular intervals from the first embryonic blood vessel,
the dorsal aorta (DA), to form the ISVs. Nascent ISVs then
connected with adjacent ISVs to form the dorsal longitudinal
anastomotic vessel (DLAV) at 30 hr postfertilization (30 hpf;
Figure 1A) [4, 10]. Quantification of EC numbers in sprout-
ing ISVs using a nuclear-localized endothelial-specific en-
hanced green fluorescent protein (EGFP) transgene (Tg(kdrl:
nlsEGFP)zf109 [11]) showed that ISVs at 30 hpf stereotypically
contain three to four ECs, as previously reported [4, 11] (Fig-
ure 1B). However, using established pharmacological inhibi-
tors of the Vegfr and Notch signaling pathways (SU5416 and
DAPT, respectively), we were able to precisely manipulate
sprouting EC numbers during ISV angiogenesis (Figures 1B–
1D). EC sprouting was significantly enhanced upon incubation
of embryos with DAPT from prior to ISV sprouting (22 hpf) to 30
hpf (Figures 1B and 1C), consistent with the EC hypersprouting
phenotypes observed in the absence of Notch signaling [4–6].
In contrast, EC sprouting was entirely blocked in embryos
incubated with high levels of Vegfr inhibitor (2.5 mM SU5416,
Figures 1B and 1D), as previously observed [12]. Moreover,
serial dilution of SU5416 (see Figures S1A and S1B available
online) revealed that intermediate EC-sprouting phenotypes
could be obtained upon partial inhibition of Vegfr (0.625 mM
SU5416; Figures 1B and 1D). Hence, temporal disruption of
Vegfr/Notch signaling during ISV sprouting allowed precise
pharmacological control of angiogenic versus nonangiogenic
EC behavior in vivo.
Exploiting these observations,wedefined anovel strategy to
identify genes functionally associated with EC sprouting (Fig-
ure 1E). Tg(kdrl:GFP)s843; Tg(gata1:DsRed)sd2 embryos were
incubated from 22 to 30 hpf with compounds that either
promoted (DAPT), fully repressed (2.5 mM SU5415), or partially
repressed (0.63 mM SU5416) angiogenic cell behavior in vivo
(Figures 1A–1D; Figure S1). Pharmacologically manipulated
GFP-positive ECs were then isolated by fluorescence-acti-
vated cell sorting (FACS) and separated from GFP/dsRed-
double-positive erythrocytes prior to comparison of their
transcriptomes to DMSO-treated controls. Subsequent multi-
factorial comparison of expression profiles (see Experimental
Procedures) identified109geneswhoseexpressionwas tightly
correlated with EC-sprouting levels, including flt4, the only
known TC-enriched gene in zebrafish [4] (Figure 1F; Figures
1C and S1D). Surprisingly, the most SU5415/Vegfr responsive
of these genes was a homeobox transcription factor gene,
h2.0-like homeobox-1 (hlx1) (Figure 1F; Figure S1C), which dis-
played an expression profile that was highly correlated with
EC-sprouting levels (Figure 1F; Figure S1D). Furthermore,
expression analyses revealed that compared to the pan-endo-
thelial marker kdrl [13], hlx1 was highly enriched in sprouting
ECs in vivo (Figure 1G), suggesting a key role for Hlx1 during
ISV angiogenesis. The mammalian ortholog of Hlx1 (HLX)
was originally identified as a key determinant of mammalian
liver, gut, and hematopoietic development [14–17]. Strikingly,
Figure 1. hlx1 Expression Is Associated with
Angiogenic Cell Behavior In Vivo
(A and B) Lateral views of Tg(kdrl:GFP)s843 (A)
or Tg(kdrl:nlsEGFP)zf109 (B) embryos at 30 hpf
following incubation with either 0.4% DMSO,
100 mM DAPT, 2.5 mM SU5416, or 0.625 mM
SU5416 from 22 hpf. Arrows in (A) indicate posi-
tions of the DA (dotted line in B denotes DA)
and the forming DLAV, whereas white brackets
in (A) and (B) indicate sprouting ISVs.
(C and D) Quantification of ISV EC numbers at
30 hpf upon incubation of Tg(kdrl:nlsEGFP)zf109
embryos with either 100 mM DAPT (C) or the indi-
cated concentration of SU5416 (D) (n = at least 21
embryos). A total of 100 mMDAPT augmented EC
sprouting during ISV angiogenesis, whereas 2.5
and 0.625 mM SU5416 dose dependently disrup-
ted EC-sprouting behavior.
(E) Strategy for the identification of genes associ-
ated with EC-sprouting behavior in vivo. EC
sprouting was pharmacologically manipulated
prior to FACS-mediated isolation and transcrip-
tome profiling of kdrl:GFP-positive ECs from
dissected zebrafish trunks containing sprouting
ISVs. Contaminating kdrl:GFP- and gata1:dsRed-
double-positive erythrocytes were removed dur-
ing FACS.
(F) Fold change in EC hlx1 expression upon incu-
bation with the indicated chemical versus DMSO
controls. EC hlx1 expression was tightly corre-
lated with the level of EC-sprouting behavior
in vivo.
(G) Whole-mount in situ hybridization analysis of the pan-endothelial marker kdrl or hlx1 at 24 hpf. hlx1 expression was enriched in sprouting ISVs (arrows).
Error bars represent mean 6 SEM. *p < 0.05 versus control, Student’s t test.
See also Figure S1.
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tion (edema, early lethality) [16, 17], and HLX was recently
shown to influence expression of EC guidance cues in vitro
[18]. However, the vascular function of HLX/Hlx1 in vivo is
unknown.
To confirm an association of hlx1 with angiogenic cell
behavior in vivo, we assessed its spatiotemporal pattern of
expression during zebrafish development (Figures 2A–2J).
Compared with expression of the EC marker kdrl [13], hlx1
expression was not detected in the first embryonic artery
(DA), which forms by the process of vasculogenesis (red
bracket in Figures 2A and 2B) [10, 12]. However, during ISV
angiogenesis, hlx1 expressionwas enriched in the first-sprout-
ing ECs (arrows in Figures 2C and 2D). Expression of hlx1 was
also observed prior to ISV sprouting at discrete regions of
future angiogenic remodeling within the DA (arrowheads in
Figure 2D). At subsequent developmental stages hlx1 became
increasingly enriched in sprouting ISVs (Figures 2E and 2F)
and was almost exclusively restricted to angiogenic ECs at
30 hpf (Figures 2G and 2H). Similarly, sprouting angiogenic
ECs of the midcerebral veins (MCeVs) were also hlx1 enriched
(arrows in Figures 2I and 2J). However, hlx1 expression was
excluded from the adjacent nonangiogenic parental tissues
of the DA and primordial hindbrain channel (PHBC) during
ISV andMCeV angiogenesis (Figures 2G–2J). Importantly, vas-
cular expression of hlx1 was also absent in zebrafish cloche
(clos5) mutants that lack endothelial tissues [19], confirming
expression of hlx1 in sprouting ECs (Figures 2K and 2L). Fur-
thermore, EC hlx1 expression was reduced or lost upon the
SU5416-mediated disruption of ISV sprouting (Figures 2M
and 2N). In contrast, DAPT-induced EC hypersprouting pro-
moted ectopic hlx1 expression throughout the endothelium(arrowheads in Figure 2O), which could be blocked upon coin-
cubation of embryos with SU5416 (Figure 2P). Finally, mature
ISVs at stages after angiogenesis no longer expressed hlx1
(data not shown). Hence, expression of hlx1 exclusively marks
sprouting ECs and represents a unique marker of angiogenic
versus nonangiogenic ECs.
To elucidate the function of Hlx1 during ISV angiogene-
sis, we injected Tg(kdrl:GFP)s843 and Tg(kdrl:nlsEGFP)zf109 em-
bryoswith either control morpholino oligonucleotides (MOs) or
hlx1-targeting MOs that disrupted hlx1 translation or exon-
intron splicing (Figure S2). ISV sprouting in hlx1 MO-injected
(morphant) embryos was delayed at 30 hpf and severely dis-
rupted at 48 hpf (Figures 3A–3G). In particular, ISVs in hlx1
morphant embryos were predominantly stunted, failed to con-
nect with adjacent vessels, and often remained blunt ended
(asterisks in Figure 3A). Hlx1 knockdown did not notably affect
embryomorphology (Figure 3H), arterial/venous differentiation
of ECs (Figure S3A), assembly of the axial vessels (Figure 3I), or
blood flow through the DA (red arrow in Figure 3J) and cardinal
vein (blue arrow in Figure 3J). However, injection of embryos
with hlx1 MOs severely disrupted blood flow through the
ISVs (Figure 3J), consistent with inadequate angiogenesis
and reduced connections between adjacent vessels (Figures
3A and 3I). Importantly, perturbed ISV sprouting was associ-
ated with decreased incorporation of ECs into sprouting
vessels (Figures 3D–3F) and reduced EC proliferation (Fig-
ure 3G). Hence, consistent with its specific expression in
sprouting ECs, hlx1 appears to be essential for ISV angiogen-
esis during zebrafish development.
Signaling via the Vegf-Notch axis promotes TC specification
and behavior, at least in part, by inducing the TC-restricted
expression of flt4 [4, 13, 20]. Consequently, flt4 morphant
Figure 2. hlx1 Expression Marks Sprouting ECs
Whole-mount in situ hybridization analysis of kdrl
(A, C, E, G, I, and K) or hlx1 (B, D, F, H, J, and L–P)
expression at 18 (A andB), 22 (C andD), 28 (E, F, I,
and J), or 30 (G, H, and K–P) hpf in untreated WT
embryos (A–J), clos5 mutant embryos (K and L),
or WT embryos incubated with DMSO (M),
0.625 mM SU5416 (N), 100 mM DAPT (O), or both
100 mM DAPT and 0.625 mM SU5416 (P) from
22 hpf (A–J; red brackets in A–H mark the DA,
whereas blue brackets in C–H mark the cardinal
vein). hlx1 is not expressed during early vasculo-
genic assembly of the DA (B) but is initially ex-
pressed in the first-sprouting ISVs (arrows in C
and D) and at regions of future angiogenic re-
modeling (arrowheads in D). At later stages hlx1
expression is almost exclusively restricted to
sprouting angiogenic ECs of the ISVs (arrows in
E–H) and MCeVs (arrows in I and J) but is
excluded from the adjacent nonangiogenic
parental tissues of the DA (red brackets in A–H)
and PHBC (arrowheads in I and J). (K and L)
Both kdrl and hlx1 expressions are reduced or
lost in EC-deficient clos5 mutants. Arrowheads
in (L) indicate nonendothelial staining of the
ventral somite. (M–P) SU5416-mediated sup-
pression of EC sprouting abolished hlx1 ex-
pression (N), whereas DAPT promoted ectopic
hlx1 expression in nonangiogenic tissues (arrow-
heads in O). DAPT-induced expression of hlx1
was lost upon coincubation of embryos with the
VEGFR inhibitor, SU5416 (P) (LLP, putative lateral
line primordium).
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1791embryos display defects in EC sprouting similar to those
observed upon Hlx1 knockdown [4]. However, TC-associated
expression of flt4was comparable to controls in hlx1morphant
embryos, indicating that TC specification was unaffected
(Figure S3A). Furthermore, observations that EC sprouting in
hlx1 morphants was highly Flt4 dependent (Figures S3B and
S3C) suggested that Hlx1-compromised ISVs still displayed
TC behavior. Moreover, live-imaging analyses of Tg(kdrl:
nlsEGFP)zf109 embryos revealed that the initial timing of TC
migration was also unaffected in hlx1 morphant embryos
(Movies S1 and S2). However, the hierarchical organization
of sprouting cells was disrupted in hlx1 morphants versus
controls (Movie S2). In particular, unlike in controls, sprouting
ECs in hlx1morphants did not rapidly sort into leading TCs and
trailing SCs but appeared to display prolonged competition for
the TC position (see ISVs B and C in Movie S2). Consequently,
we hypothesized that Hlx1may alternatively influence SC iden-
tity. Consistent with this hypothesis, we observed that hlx1
was uniquely expressed in the SC domain (as well as in TCs)
during ISV sprouting (Figures 4A–4D). Whereas all vessels
expressed the pan-endothelial marker kdrl (Figure 4A), hlx1
expression was restricted to angiogenic-sprouting cells of
the ISVs (Figure 4B). However, unlike expression of flt4, whichwas restricted to the TC domain of
sprouting ISVs (Figure 4C), hlx1 expres-
sion was expanded throughout the
SC domain (Figure 4B). Moreover, hlx1
was excluded from adjacent nonangio-
genic ECs (or ‘‘phalanx’’ cells [21]) of
the DA, which express high levels of
efnb2a (Figure 4D) [22]. Other SC-en-
riched genes, such as flt1 and tie2, arealso expressed at high levels in adjacent nonangiogenic
tissues [23, 24]. Hence, to the best of our knowledge, hlx1
represents the first-identified discriminative marker of sprout-
ing SCs versus nonangiogenic ECs.
SC-enriched expression suggested that hlx1 influences SC
identity. To elucidate the cell-autonomous role of Hlx1 in SC
fate decisions at single-cell resolution, we transplanted cells
from Tg(kdrl:GFP)s843 embryos into nontransgenic hosts. Pre-
vious studies have determined that the TC and SC potential of
ECs can be assessed during zebrafish development based
on the ability of transplanted ECs to contribute to the DLAV
or ISV stalk position, respectively [4, 25, 26]. Hlx1 alone was
not sufficient to induce SC fate because hlx1-RNA-injected
donors contributed to the DLAV and ISV stalk positions with
a similar frequency as controls (Figures 4E and 4F; Table S1).
However, unlike controls, cells transplanted from hlx1-MO-in-
jected donors frequently contributed exclusively to the DLAV
position of ISVs (Tip, Figure 4E). Importantly, quantification
of the positional fates of donor cells within ISVs confirmed
that Hlx1-knockdown ECs were less likely to acquire SC fate,
preferentially migrated to the DLAV position, and were found
exclusively at the DLAV position of at least 42% of sprouting
ISVs (Figure 4F; Table S1). Furthermore, live-imaging studies
Figure 3. Hlx1 Is Required for ISV Angiogenesis In Vivo
(A–F) Lateral views of Tg(kdrl:GFP)s843 (A) or Tg(kdrl:nlsEGFP)zf109 (D; dotted line represents position of the DA) embryos and quantification of ISV
morphology (B and C; ‘‘half DLAV’’ refers to ISVs connected to only one adjacent ISV; n = at least 20 embryos) or ISV EC numbers (E and F; n = at least
15 embryos) at 30 (B and E) and 48 (C and F) hpf upon injection with either control MO (Con. MO) or hlx1 MO.
(G) Quantification of the number of dividing ECs per ISV following live imaging of control or hlx1MO-injected embryos from 19 hpf for approximately 13 hr (n =
at least 30 ISVs from a total of 8 embryos).
(H and I) Lateral views of control or hlx1 MO-injected Tg(kdrl:GFP)s843 embryos at 48 hpf (red arrows indicate DA; blue arrows denote cardinal vein).
Hlx1 knockdown disrupts ISV sprouting (as indicated by asterisks in A and arrowheads in I), limits EC incorporation into ISVs (D–F), and reduces EC prolif-
eration (G).
(J) Lateral views of control or hlx1morphants upon injection of FITC-dextran into the blood flow to assess vascular patterning at 48 hpf. White arrows indi-
cate ISVs lacking blood perfusion. Red and blue arrows indicate arterial and venous blood flow, respectively. Arrowheads indicate ISVs that lack connec-
tions with adjacent ISVs. Blood flow through ISVs is disrupted upon Hlx1 knockdown.
Error bars represent mean 6 SEM. *p < 0.05 versus control, Student’s t test.
See also Figures S2 and S3 and Movies S1 and S2.
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unlike controls, frequently exclusively occupied the leading TC
position and did not contribute to ISV SCs (Movies S3 and S4).
These data lead us to propose that Hlx1 functions cell-auton-
omously to reinforce and maintain SC potential during ISV
sprouting (Figure 4G). Hence, Hlx1 regulates angiogenesis by
influencing the outcome of EC competition for the TC position.
Previous work has primarily focused on defining the roles of
VEGFR and Notch signaling in TC formation during new blood
vessel sprouting [3–8]. Here, we show that Hlx1-mediated
maintenance of SC potential appears to be critical for normal
ISV angiogenesis in vivo (Figure 3). Whereas TCs express
high levels of promigratory genes (such as vegfr2 and flt4) [4,
6, 20] and are highly motile, SCs need to be characteristically
less motile to maintain their position behind TCs. HLX was
recently found to impede the migratory behavior of ECs
in vitro by inducing the expression of repulsive guidancemole-
cules such as UNC5B [18]. Hence, Hlx1-mediated repression
of EC migration may be critical for determining SC positioning
and functional blood vessel sprouting. In addition, our findings
indicate that Hlx1 may also positively influence EC prolifera-
tion, because a decrease in cell divisions was observed in
the ISVs of hlx1 morphant embryos (Figure 3G). Moreover,
this proliferation defect may account, at least in part, for thereduced number of ECs in the sprouting ISVs of hlx1 mor-
phants (Figures 3D–3F), which contrasts sharply with the hy-
persprouting phenotype observed in mosaic hlx1-deficient
ECs (Figures 4E and 4F). Most importantly, our findings
provide new evidence that reinforcement of SC identity and
positional fate is critical for angiogenesis and implicate Hlx1
in this process. Hence, a fine balance between TC- and SC-
inducing signals is crucial for the coordinated sprouting of
new blood vessels. Considering the potential therapeutic
implications of manipulating SC formation during pathological
angiogenesis [27], future studies defining the downstream
transcriptional network and precise cellular mechanisms of
Hlx1 function in vivo will be of great importance. Furthermore,
because the global mechanisms controlling angiogenesis and
the branching morphogenesis of various epithelial tissues
appear to be highly conserved [1], our findings raise the excit-
ing possibility that analogous mechanisms may also control
SC identity in other systems.Supplemental Information
Supplemental Information includes three figures, one table, Supplemental
Experimental Procedures, and fourmovies and can be foundwith this article
online at http://dx.doi.org/10.1016/j.cub.2012.07.037.
Figure 4. Hlx1 Cell-Autonomously Maintains Endothelial SC Potential
(A–D) Whole-mount in situ hybridization analysis of kdrl (A), hlx1 (B), flt4 (C),
and efnb2a (D) at 30 hpf and diagrams displaying the expression domain of
each gene (V, cardinal vein; A, DA; arrowhead indicates SC; asterisks denote
TC). Whereas flt4marks only TCs (C), hlx1 uniquelymarks SCs (and possibly
TCs) of the sprouting ISVs (B) and is excluded from nonangiogenic ECs of
the DA, which express high levels of efnb2a (D).
(E) Lateral images of control MO, hlx1 MO, or hlx1 RNA-injected donor
Tg(kdrl:GFP)s843 cells in nontransgenic hosts at 30 hpf (dotted line repre-
sents position of the WT vasculature).
(F) Quantification of the incorporation of donor cells into the DLAV position
(asterisks in E) or stalk position (arrowheads in E) of individual host ISVs (n =
at least 44 ISVs; control = 19 embryos; hlx1 MO, 17 embryos; hlx1 RNA, 26
embryos). When hlx1 is knocked down, ECs are lost from the ISV stalk posi-
tion and accumulate in the DLAV position of sprouting ISVs.
(G) Model summarizing the EC-autonomous function of Hlx1 during ISV
angiogenesis.
See also Figure S4, Movies S3 and S4, and Table S1.
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